Barinthus Biotherapeutics posted a Q2 net loss attributable to shareholders of USD 10.6 million, or USD 0.26 per share, worsening from Q1’s USD 5.5 million loss.
Research and development expense rose 9.18% quarter-on-quarter to USD 3.92 million, driven by higher VTP-1000 celiac program costs.
General and administrative costs more than doubled to USD 7.1 million on higher unrealized FX losses and increased professional fees.
Cash, cash equivalents and restricted cash fell to USD 59.6 million as of June 30 from USD 67.2 million at March 31.
Completed enrollment of 42 subjects in the Phase 1 AVALON VTP-1000 celiac trial; MAD topline data expected in Q4 2026, with a proposed Clywedog merger targeted for H2 2026.
BRNS•
